Patient details and prior therapy
| . | LGNHL . | HGNHL . | HD . | MCL . |
|---|---|---|---|---|
| No. of patients | 52 | 62 | 52 | 22 |
| Age at RIT, median (range) | 46 (27-65) | 43 (2-61) | 30 (15-53) | 52 (44-57) |
| Months from diagnosis to NST, median (range) | 33 (6-289) | 21 (3-205) | 42 (7-223) | 35 (5-96) |
| No. of prior lines of therapy, median (range) | 3 (1-5) | 3 (1-5) | 3 (1-6) | 2 (1-5) |
| Prior autograft, % | 29 | 52 | 69 | 36 |
| Disease status at RIT, no. patients (%) | ||||
| Chemosensitive | 44 (85) | 45 (73) | 28 (54) | 16 (73) |
| Chemoresistant | 5 (10) | 13 (21) | 19 (37) | 3 (14) |
| Untested relapse | 3 (6) | 4 (6) | 5 (10) | 3 (14) |
| . | LGNHL . | HGNHL . | HD . | MCL . |
|---|---|---|---|---|
| No. of patients | 52 | 62 | 52 | 22 |
| Age at RIT, median (range) | 46 (27-65) | 43 (2-61) | 30 (15-53) | 52 (44-57) |
| Months from diagnosis to NST, median (range) | 33 (6-289) | 21 (3-205) | 42 (7-223) | 35 (5-96) |
| No. of prior lines of therapy, median (range) | 3 (1-5) | 3 (1-5) | 3 (1-6) | 2 (1-5) |
| Prior autograft, % | 29 | 52 | 69 | 36 |
| Disease status at RIT, no. patients (%) | ||||
| Chemosensitive | 44 (85) | 45 (73) | 28 (54) | 16 (73) |
| Chemoresistant | 5 (10) | 13 (21) | 19 (37) | 3 (14) |
| Untested relapse | 3 (6) | 4 (6) | 5 (10) | 3 (14) |